$MRUS $BCAX interesting on the mDOR front. always read the swimmer plots

IF we exclude the HPV positive patients from the MRUS phase 1/2 trial of petosemtamab, the mDOR = 12-14 months. They got a bit lucky with mDOR = "NR" with 14/27 still going, but of those 27 responders, 4 are HPV pos (blue), 3 are still on treatment . Compare to BCAX with mDOR 21 months, (although barely).

Also note, if we use the unconfirmed ORR from BCAX ficerafusp and exclude HPV negative patients from MRUS (both optimistic, yes I know). the responder rate looks fairly similar stratified by PD1 status. 50% vs 47% in CPS < 20 and 76% vs 73% in > 20.

Not saying to long either either. We need to see 1) tumor size/status for the MRUS dataset (i/e LR vs distant mets) 2) confirmed responses from BCAX 3) swimmer plot for BCAX.

BUT MRUS is currently valued at 5B MC and BCAX at 600M. The r/r here is skewed. I await for the next update. There could be a real pitch that BCAX durability is longer.